Table 4 Responder Analyses
% Pain reduction | Treatment groups | Group differences (95% CI) | ||||
|---|---|---|---|---|---|---|
|  | SMT + HEP | SEP + HEP | HEP | SMT + HEP minus HEP | SEP + HEP minus HEP | SMT + HEP minus SEP + HEP |
Week 12a | ||||||
 No reduction or worsening | 13.8 | 20.3 | 29.0 | −15.2 (− 27.7 to 2.3) | −8.7 (− 22.0 to 4.9) | − 6.5 (− 18.2 to 5.3) |
  ≥ 30% | 68.8 | 65.8 | 52.6 | 16.1 (0.8 to 30.5) | 13.2 (−2.2 to 27.8) | 2.9 (− 11.5 to 17.2) |
  ≥ 50% | 52.5 | 43.0 | 34.2 | 18.3 (2.7 to 32.6) | 8.8 (−6.4 to 23.5) | 9.5 (−5.9 to 24.3) |
  ≥ 75% | 20.0 | 12.7 | 10.5 | 9.5 (−2.0 to 20.7) | 2.1 (−8.4 to 12.6) | 7.3 (−4.3 to 18.9) |
 100% | 5.0 | 6.3 | 1.3 | 3.7 (−2.8 to 10.9) | 5.0 (−1.8 to 12.7) | −1.3 (−9.6 to 6.7) |
Week 26b | ||||||
 No reduction or worsening | 25.3 | 26.6 | 19.5 | 5.8 (−7.3 to 18.7) | 7.1 (−6.2 to 20.0) | − 1.3 (− 14.8 to 12.3) |
 ≥ 30% | 49.4 | 53.2 | 52.0 | −2.6 (− 17.8 to 12.8) | 1.2 (−14.1 to 16.5) | −3.8 (− 18.9 to 11.5) |
 ≥ 50% | 32.9 | 30.4 | 32.5 | 0.4 (− 14.1 to 14.9) | −2.1 (− 16.4 to 12.3) | 2.5 (− 11.8 to 16.7) |
 ≥ 75% | 12.7 | 16.5 | 14.3 | −1.6 (− 12.7 to 9.3) | 2.2 (−9.4 to 13.6) | − 3.8 (− 15.0 to 7.4) |
 100% | 5.1 | 5.1 | 5.2 | −0.1 (−8.2 to 7.8) | − 0.1 (− 8.2 to 7.8) | 0.0 (− 7.9 to 7.9) |
Week 52c | ||||||
 No reduction or worsening | 23.8 | 27.9 | 31.6 | −7.8 (−21.5 to 6.1) | −3.7 (−17.8 to 10.5) | −4.1 (− 17.5 to 9.4) |
 ≥ 30% | 47.5 | 49.4 | 52.6 | −5.1 (−20.3 to 10.3) | −3.3 (− 18.5 to 12.2) | − 1.9 (− 17.0 to 13.4) |
 ≥ 50% | 35.0 | 27.9 | 38.2 | − 3.2 (− 17.9 to 11.7) | −10.3 (− 24.5 to 4.4) | 7.2 (− 7.2 to 21.1) |
 ≥ 75% | 7.5 | 15.2 | 14.5 | −7.0 (− 17.4 to 3.1) | 0.7 (− 10.8 to 12.1) | − 7.7 (− 18.0 to 2.4) |
 100% | 3.8 | 5.1 | 2.6 | 1.1 (− 5.8 to 8.1) | 2.4 (− 4.7 to 9.9) | − 1.3 (− 9.0 to 6.1) |